Cellular Immunotherapy Market Report 2024 Key Players, Size, Share, Trends, Growth And Forecast 2033

The cellular immunotherapy market size has grown rapidly in recent years. It will grow from $4.99 billion in 2023 to $5.78 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to cancer treatment advancements, clinical success stories, regulatory approvals, growing incidence of targeted diseases.

The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $9.95 billion in 2028 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to expansion to solid tumors, improved manufacturing, healthcare infrastructure, research funding. Major trends in the forecast period include research and development investments, clinical trial data, combination therapies.

Market Overview -
Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body's immune system to combat cancer.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Expanding Cellular Immunotherapy Market Driven By Research And Clinical Advancements
Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. For instance, in June 2022, according to a report published by the Cancer Research Institute, a US-based nonprofit organization devoted solely to developing immunotherapy for the prevention, treatment, and eventual eradication of all cancers, in the worldwide immuno-oncology pipeline as of April 2022, there were 2,756 active cell therapy drugs, up 36% from the landscape analysis of 2021 that revealed 2,031 such agents but also a slight slowdown from the 43% growth in the previous year. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the growth of the cellular immunotherapy market.

Competitive Landscape -
Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Advancements In Cellular Immunotherapy A Rise Of Off-The-Shelf Allogeneic Therapies
Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient's cells, as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast production, and quality control. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of drugs, announced that after two or more lines of systemic therapy, the US Food and Drug Administration (FDA) has given expedited approval for Kymriah (tisagenlecleucel) to treat adult patients with relapsed or refractory (r/r) follicular lymphoma (FL). In addition, Acepodia, a US-based next-generation cell immuno-technology company, will begin a phase 1 clinical trial in August 2020 to evaluate ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Key Segments -
The cellular immunotherapy market covered in this report is segmented -
1) By Therapy: Tumour-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.